Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy

Next Previous
Trial Profile

A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology

Most Recent Events

  • 15 May 2020 According to a Takeda China media release, ADCETRIS (brentuximab vedotin) has been officially approved by Chinas National Medical Products Administration (NMPA) for use in adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL) or CD30-positive Hodgkin Lymphoma. The local approval of ADCETRIS in China is based on the data from clinical studies SG035-0004, SG035-0003 and C25007.
  • 22 Apr 2020 Status changed from active, no longer recruiting to completed.
  • 29 Jan 2018 Results (n=380) of pooled data from six trials assessing population pk and exposure-response relationships for the antibody-drug conjugate brentuximab vedotin in ctcl patients, were published in the Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top